Since 2018, Denmark has operated a Pilot Programme for medical cannabis, which is scheduled to expire in December 2025. Through this initiative, Denmark has positioned itself as a European leader in prescription-based medical cannabis. According to the official evaluation of the Programme, many patients have reported positive treatment outcomes when using medical cannabis as an alternative to conventional therapies.

In November 2024, the Danish Parliament decided to make the use of medical cannabis a permanent option, bringing clarity and long-term stability to the industry. Stenocare, currently the leading supplier of medical cannabis oil products in Denmark, welcomes the decision as a significant milestone for the industry.

Stenocare has actively engaged with health authorities and policymakers throughout the Pilot Programme, offering insights to support an informed decision on permanent legalization. On April 24, 2025, the Danish Parliament formally adopted "Bill L135" that establishes the permanent legislative framework for the medical use of cannabis. The law will take effect on January 1, 2026.

The political approval provides reassurance and predictability for patients who may have been concerned about the future of their treatment. The decision includes several improvements that will benefit patients. These include updated guidance from the Danish Medicines Agency to support doctors in confidently prescribing medical cannabis. In addition, the Danish Patient Safety Authority will revise the health criteria used in its recommendations regarding driving restrictions for patients undergoing cannabis treatment. Importantly, the 50% subsidy for medical cannabis products will remain unchanged under the new law.

Stenocare CEO, Thomas Skovlund Schnegelsberg, comments:

"This is a day of celebration. Uncertainty has been replaced by a clear and positive decision to permanently allow treatment with medical cannabis in Denmark. This is a victory for patients, who can now continue their treatment without being forced to obtain their medicine from the illegal market. It is also a win for Stenocare and our significant investments in making medical cannabis oil products available. With this win-win outcome, Denmark continues its leadership role in Europe by ensuring patient access to a proven alternative in medical cannabis."

Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/ to automatically receive the latest news and information about the Company.